<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01748084</url>
  </required_header>
  <id_info>
    <org_study_id>P110110</org_study_id>
    <secondary_id>2012-001636-56</secondary_id>
    <nct_id>NCT01748084</nct_id>
  </id_info>
  <brief_title>Rituximab in Systemic Sclerosis</brief_title>
  <acronym>RECOVER</acronym>
  <official_title>Evaluation of Rituximab in Systemic Sclerosis Associated Polyarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether rituximab is effective in the treatment of
      articular symptoms that occur in systemic sclerosis related polyarthritis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic sclerosis (SSc) is a rare disease, characterized by microvascular and immunological
      changes promoting extra-cellular matrix synthesis and widespread fibrosis. No treatment has
      yet proven any ability to alter the disease fibrosing process. Specific auto-antibodies are
      commonly found in this disease, and B lymphocytes are detected in cutaneous and pulmonary
      infiltrates. Studies derived from murine models suggest a role for B lymphocyte blocking
      strategies.

      This lead to observational trials of B-cell therapy using rituximab in SSc that provided
      encouraging results with no particular signal concerning tolerability. These trials included
      heterogeneous patients with variable disease stages and different involved organs, and were
      mostly unblinded, which preclude any definitive conclusion. However, they support the
      continuous development of this therapeutic approach.

      Taking up the early phase of the diffuse form of the disease is complicated by its rarity and
      the heterogeneous progression of its visceral complications. This raises the question of
      selecting a homogeneous group of patients to evaluate. The most convincing results for the
      use of rituximab in autoimmune conditions have been found in rheumatoid arthritis. Joint
      involvement is common in SSc with 75% of patients complaining about joint stiffness and pain,
      and 30% presenting with synovitis, tenosynovitis, or flexion contractures. No specific
      treatment has already addressed this issue, and it is generally proposed to use small doses
      of oral corticosteroids in association with methotrexate, by analogy with rheumatoid
      arthritis. We propose to evaluate the efficacy and safety of rituximab in SSc patients having
      active arthritis despite first line treatment. Improving the articular involvement would
      improve the quality of life f SSc patients and effectiveness of rituximab on skin and lung
      fibrotic involvements will be assessed as secondary outcomes to estimate the overall effects
      of this drug on SSc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2013</start_date>
  <completion_date type="Actual">April 18, 2016</completion_date>
  <primary_completion_date type="Actual">April 18, 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of tender and swollen joints</measure>
    <time_frame>at 6 months</time_frame>
    <description>Measured out of 53 joints</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life: SSc-HAQ</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <description>Validated scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scleroderma</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <description>modified Rodnan skin score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung fibrosis</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <description>Pulmonary functional tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: SF-36</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <description>Validated scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: Duruöz index</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <description>Validated scores</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>NaCl</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl 500 ml IV day 1 and day 15 plus 100 mg methylprednisolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab 1G IV day 1 and day 15 plus 100 mg methylprednisolone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Days 1 and 15, rituximab 1 gramme plus 100 mg methylprednisolone</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (NaCl)</intervention_name>
    <description>Days 1 and 15, NaCl 500 ml plus 100 mg methylprednisolone</description>
    <arm_group_label>NaCl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Systemic sclerosis fulfilling ACR or LeRoy's criteria

          -  Active polyarthritis defined by &gt; 6/53 tender joints and &gt; 4/53 swollen joints

          -  Ongoing first line therapy by prednisone (max 10 mg/d) and DMARDS (methotrexate,
             leflunomide, azathioprine or mycophenolate)

          -  Birth control if applicable

        Exclusion Criteria:

          -  Overlap syndrome defined by clinical symptoms and positive specific auto-antibodies
             (anti-CCP, anti-SSA, anti-DNA DNA anti-Sm) (Rheumatoid factors and anti-RNP are not
             exclusion criteria)

          -  Past therapy with Rituximab.

          -  Severe and uncontrolled disease with renal, liver or haematological (neutropenia &lt;
             1500 / mm3) failures, pulmonary (FVC &lt; 50%) or cardiac insufficiencies (LVEF &lt; 50%)

          -  Not stable corticosteroid therapy or cyclophosphamide use in the last 6 months

          -  Infectious risk : viral infections by B or C hepatitis or HIV, hypogammaglobulinemia
             (&lt; 6 G/L), opportunistic infection or infection requiring IV antibiotics in the last 3
             months.

          -  Neoplastic solid tumor in the last 5 years

          -  Drug or alcool abuses

          -  Receiving patient or having received a biotherapy (anti-TNF, abatacept or tocilizumab)
             in the last 3 months (possible inclusion beyond 3 months)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yannick Allanore, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique Hôpitaux de Paris, Université Paris Descartes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bosello S, De Santis M, Lama G, Spanò C, Angelucci C, Tolusso B, Sica G, Ferraccioli G. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther. 2010;12(2):R54. doi: 10.1186/ar2965. Epub 2010 Mar 25.</citation>
    <PMID>20338043</PMID>
  </reference>
  <reference>
    <citation>Simms RW, Lafyatis R. Rituximab: a potential therapeutic advance in scleroderma: what is the evidence? Rheumatology (Oxford). 2010 Feb;49(2):201-2. doi: 10.1093/rheumatology/kep421. Epub 2009 Dec 23.</citation>
    <PMID>20032221</PMID>
  </reference>
  <reference>
    <citation>Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Korfiatis P, Yiannopoulos G, Andonopoulos AP. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum. 2010 Oct;40(2):127-36. doi: 10.1016/j.semarthrit.2009.09.003. Epub 2009 Dec 11. Review.</citation>
    <PMID>20004954</PMID>
  </reference>
  <reference>
    <citation>Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010 Feb;49(2):271-80. doi: 10.1093/rheumatology/kep093. Epub 2009 May 15.</citation>
    <PMID>19447770</PMID>
  </reference>
  <reference>
    <citation>Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009 Feb;60(2):578-83. doi: 10.1002/art.24249.</citation>
    <PMID>19180481</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2012</study_first_submitted>
  <study_first_submitted_qc>December 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2012</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic sclerosis</keyword>
  <keyword>Arthritis</keyword>
  <keyword>B-cell therapy, Anti-CD20 therapy</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Scleroderma</keyword>
  <keyword>Lung fibrosis</keyword>
  <keyword>Randomised controled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

